Back to today’s briefing

Story perspectives

Breakthrough Depression Treatment Shows Promise in Phase 2b Trial

7/2/2025

35 7

Summary

Story summary

Atai Life Sciences and Beckley Psytech have unveiled promising results from their phase 2b trial of BPL-003, aimed at treating resistant depression. Involving 193 participants across six countries, the study revealed remarkable decreases in depressive symptoms following just one dose. With the 8 mg and 12 mg doses proving safe, they are now gearing up for phase 3 trials.

1 of 1

Story summary

Atai Life Sciences and Beckley Psytech have unveiled promising results from their phase 2b trial of BPL-003, aimed at treating resistant depression. Involving 193 participants across six countries, the study revealed remarkable decreases in depressive symptoms following just one dose. With the 8 mg and 12 mg doses proving safe, they are now gearing up for phase 3 trials.